Clinical Edge Journal Scan

Joint damage repair: A rare phenomenon in early RA


 

Key clinical point: Repair of joint space narrowing occurred but was rare in patients with early rheumatoid arthritis (RA) who underwent 8 years of treatment to a target disease activity score (DAS) 2.4. Therefore, suppression of damage progression should be the focus of clinical care.

Major finding: Only 5.3% of patients showed repair of joint space narrowing and bone erosions after 8 years of treatment to a target of DAS 2.4. No significant association was observed between achieving repair and suppression of disease activity, duration of previous remission, or other predictors of repair.

Study details: Findings are from a subanalysis of BeSt study including 508 patients with severe early RA who were treated to a target of DAS 2.4 and followed for 8 years.

Disclosures: The BeSt study was supported by grants from the Dutch College of Health Insurances, Schering-Plough B.V., and Janssen B.V. The authors did not declare any conflicts of interest.

Source: van der Pol JA et al. Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: A subanalysis after 8 years treat-to-target in the BeSt-trial. RMD Open. 2023;9(2):e002995 (Apr 25). Doi: 10.1136/rmdopen-2023-002995

Recommended Reading

RA raises risk for bronchial asthma and asthma-related comorbidities
MDedge Rheumatology
Mortality risk accrues with time after diagnosis of RA
MDedge Rheumatology
RA causally associated with ischemic heart disease and myocardial infarction
MDedge Rheumatology
Looking at diseases associated with RA, May 2023
MDedge Rheumatology
Researchers seek to understand post-COVID autoimmune disease risk
MDedge Rheumatology
FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
MDedge Rheumatology
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
MDedge Rheumatology
Rheumatoid arthritis linked to increased Parkinson’s risk
MDedge Rheumatology
Investigational drug peresolimab shows efficacy in patients with RA
MDedge Rheumatology
Strong link between polycyclic aromatic hydrocarbons and raised rheumatoid arthritis risk
MDedge Rheumatology